Attributable mortality of nosocomial Acinetobacter bacteremia

Infection Control and Hospital Epidemiology

Volumn 28, Issue 3, 2007, Pages 293-298

  Grupper, Mordechai ^a   Sprecher, Hanna ^a   Mashiach, Tania ^a   Finkelstein, Renato ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; COLISTIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PARAMETER; RISK ASSESSMENT;

ACINETOBACTER; ACINETOBACTER INFECTIONS; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 33947605898     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/512629     Document Type: Article

References (24)

1. Urban C, Segal-Maurer S, Rahal J. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36:1268-1274.
2. Bergogne-Berezin E, Towner KL. Acinetobacter spp. as nosocomial pathogens: microbiologic, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148-165.
3. Garmendia JLG, Leyba OC, Montero JG, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001; 33:939-946.
4. Allen DM, Hartman BJ. Acinetobacter species. In: Mandell G, Bennett J, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Elsevier, 2005:2632-2636.
5. Siau H, Yuen KY, Ho PL, Wong SS, Woo PCY. Acinetobacter bacteremia in Hong Kong: prospective study and review. Clin Infect Dis 1999; 28: 26-30.
6. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000; 31:690-7.
7. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995; 74:340-349.
8. Jerassy Z, Yinnon AM, Mazouz-Cohen S, et al. Prospective hospital-wide studies of 505 patients with nosocomial bacteremia in 1997 and 2002. J Hosp Infect 2006; 62:230-236.
9. Wisplinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999; 28:59-66.
10. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003; 29:471-5.
11. McCabe WR, Jackson GG. Gram negative bacteremia: 1. etiology and ecology. Arch Intern Med 1962; 110:845-855.
12. National Committee for Clinical Laboratory Standards . Performance standards for antimicrobial disk susceptibility testing. Disk Diffusion Supplemental Table. Approved standard M100-S10 (M2). Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
13. Freid VM, Prager K, MacKay AP, Xia H. Health, United States, 2003. Hyattsville, Maryland: National Center for Health Statistics, 2003.
14. Vallés J, León C, Alvarez-Lerma F, for the Spanish Collaborative Group of Infections in Intensive Care Unit of SEMIUC. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Clin Infect Dis 1997; 24:387-395.
15. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infections in critically ill patients: excess length of stay, extra cost, and attributable mortality. JAMA 1994; 271:1598-1601.
16. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmont MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317.
17. Cisneros JM, Reyes MJ, Pachon J, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22:1026-1032.
18. Martin MA, Pfaller MA, Wenzel RP. Coagulase-negative staphylococcal bacteremia, mortality and hospital stay. Ann Intern Med 1989; 110:9-16.
19. Senol E, Desjardin J, Stark PC, Barefoot SL, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002; 34:1653-1656.
20. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-1177.
21. Girou E, Stephan F, Novara A, Safar M, Fagon JY. Risk factors and outcome of nosocomial infections: results of matched case-control study of ICU patients. Am J Resp Crit Care Med 1998; 157:1151-1158
22. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol 1999; 20:396-401.
23. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993; 37:750-753.
24. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46:1946-1952.